EDI and IntraMed are committed to providing customers with innovative, rapid diagnostics that meet the changing needs of the market,” says Paul Johnson, CEO of Express Diagnostics.
Blue Earth, Minn. (PRWEB) April 11, 2013
Express Diagnostics Intʼl, Inc. (EDI), and its subsidiary, IntraMed Diagnostics, LLC (IntraMed), today announced that it had acquired an option to purchase and develop all of the point-of-care (POC) clinical diagnostic testing assets of Eveia Medical, Inc., based in Boulder, Colo. Eveia is a developer of biomarker discovery systems that allow for rapid, reliable measurement of biomarkers without instrumentation.
“EDI and IntraMed are committed to providing customers with innovative, rapid diagnostics that meet the changing needs of the market,” says Paul Johnson, CEO of Express Diagnostics. “The acquisition of Eveia Medical’s technologies in rapid point-of-care testing allows us to expand our presence in health diagnostics while leveraging groundbreaking capabilities to further advance our core business of onsite drugs of abuse screening devices.”
Eveia Medical is developing rapid point-of-care (POC) technologies that enable cost-effective management of many of the most common disease states and eliminate the need for any instrumentation or reagents. The company’s proprietary point-of-care testing platforms will enable healthcare providers and life science researchers to better manage patients, diagnose disease, and develop targeted therapeutics and diagnostics.
Eveia’s patent pending cell quantitation technology is incorporated into EDI’s AnemiaCheck™ POC Quantitative Hematocrit Test, which will be available for export in Q2 2013. Single-use devices in development, utilizing the company’s patent pending ArcFlow Point-of-Care Platform, include tests for coagulation rates (blood thinners), C-Reactive Protein (CRP), HbA1c, and numerous other applications in clinical diagnostics. The technology is based on competitive flow, automatically measuring the rate at which a sample moves through specially-treated paper substrates to determine the concentrations of selected clinical biomarkers.
“We are very pleased to be partnering with Express Diagnostics through the transfer of this extensive portfolio of point-of-care technologies,” says Mike Treble, CEO of Eveia Medical. “Express Diagnostics has demonstrated an ability to drive product innovations in onsite drugs of abuse testing and generate revenue through a strong sales and distribution channel. We look forward to full commercialization of the Eveia platforms over the coming years under the direction of Express Diagnostics.”
Steve Tyrrell joins Express Diagnostics as Vice President of Research & Development
Express Diagnostics Int’l (EDI) also announced today that Steve Tyrrell has joined the company as vice president of research and development (R&D). In the role, he will oversee the organization’s R&D and serve as a technical advisor for innovation and new product technology.
“We are very excited to welcome Steve as vice president of R&D,” says Rich Strasser, COO. “EDI will utilize his expertise for not only developing new technologies, but also improving current product lines. Steve’s background in all stages of IVD discovery and product development will be a great asset to the organization as we enter new markets and work to transform existing ones.”
Tyrrell has over 25 years of experience in the clinical laboratory and in vitro diagnostics (IVD) industries and most recently served as chief technical officer at Eveia Medical, Inc., where he was a co-founder and lead inventor of the company’s technologies. His previous positions include: Interim head of R&D for AspenBio Pharma – where he lead discovery and early development of a first of its kind blood test for acute appendicitis; vice president and director of R&D at Biosafe Laboratories, Inc.; and R&D manager at Osborn Laboratories.
“Throughout my career I have taken in vitro diagnostic test systems from early concept stages to market, typically starting from my own ideas and inventions,” says Tyrrell. “This has permitted me to achieve a level of expertise in managing the diverse teams needed to bring a new IVD to market.”
He played a primary role in the development of EDI’s newest point-of-care (POC) device, the AnemiaCheck™ POC Quantitative Hematocrit Test. Pre-clinical versions of the instrument-free AnemiaCheck were introduced in the fourth quarter of 2012 and the device was recognized as a top 10 finalist in the 2012 LifeScience Alley New Technology Showcase.
Tyrrell is eager to further the development of emerging and existing IVD technologies with EDI. “Broadly, my goals are twofold: To expand the EDI and IntraMed product lines into the broader health management fields by first bringing the AnemiaCheck device to market. We will then follow with testing devices for other health disorders with broad worldwide prevalence.” He adds, “Secondly, but of equal importance, I believe there are ample opportunities to enhance the performance of existing lateral flow drugs of abuse tests and dramatically decrease the costs of manufacture using a combination of hard science and modern manufacturing techniques.”
About Express Diagnostics Int’l, Inc.
Express Diagnostics Int’l manufactures and distributes DrugCheck® on-site urine and saliva screening devices for the detection of drugs of abuse, as well as a growing catalog of health screening devices. With accuracy comparable to laboratory testing, Express Diagnostics onsite devices provide a variety of industries fast, cost-effective alternatives to higher-priced lab services. Learn more at drugcheck.com.